Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy.
Xiang BaiMargaret Chia-Ying WeyElizabeth FernandezMatthew J HartJonathan GelfondAlex F BokovSheela RaniRandy StrongPublished in: Pathobiology of aging & age related diseases (2015)
Taken together, these data suggest that rapamycin, an FDA approved drug, may prove useful in the treatment of synucleinopathy.